Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability

Epilepsia

Volumn 51, Issue 6, 2010, Pages 941-950

  Bialer, Meir ^a   Midha, Kamal K ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Average bioequivalence; Generic products of antiepileptic drugs; Interchangeability; Prescribability; Scaled average bioequivalence; Switchability

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

BIOEQUIVALENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HUMANS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954627471     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02573.x     Document Type: Review

References (58)

1. American Epilepsy Society (AES). Position statement on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. http://www.AESNET.org, or http://www.ilae-epilepsy.org. November 29, 2007.
2. American Medical Association. (2002) Featured Report; Generic Drugs (A-02). http://www.ama.-assn.org/ama/pub/category/print/15279.html Last Accessed May 1, 2009.
3. Amidon GL, Lennernas H, Shah VP, Crison JR. (1995) A theoretical basis for a biopharmaceutics drug classification: the correction of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
4. Andermann F, Duh MS, Gosselin A, Paradis PE. (2007) Compulsory generic switching of antiepileptic drugs; high switchback rates to branded compounds compared with other drug classes. Epilepsia 48:464-469. (Pubitemid 46365174)
5. Anderson GD. (2008) Pharmacokinetic, pharmacodynamic and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 30:173-180.
6. Banahan BF, Bonnarens JK, Bentley JP. (1998) Generic substitution of NTI drugs: issues for formulary committee consideration. Formulary 33:1082-1096.
7. Benet LZ, Goyan JE. (1995) Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 15:433-440.
8. Benet LZ, Amidon GL, Barends DM, Lennernas H, Poli JE, Shah VP, Stavchansky SA, Yu LX. (2008) The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 52:483-488.
9. Berg MJ. (2007) What's the problem with generic antiepileptic drugs? Neurology 68:1245-1246.
10. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. (2008a) Generic substitution in the treatment of epilepsy: patient and physician perception. Epilepsy Behav 13:693-699.
11. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. (2008b) Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71:525-530.
12. Bialer M. (1992) Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clin Pharmacokinet 22:11-22.
13. Bialer M, Levy RH, Perucca E. (1998) Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit 20:56-59.
14. Bialer M. (2007) Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 48:1825-1832.
15. Blume HH, Midha KK. (1993) Bio-International 1992, Conference on bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci: 82:1186-1189
16. and Pharm Res 10: 1806-1811.
17. Boddy AW, Snikeris FC, Kringle RO, Wei GCG, Oppermann JA, Midha KK. (1995) An approach for widening the bioequivalence limits in the case of highly variable drugs. Pharm Re 112:1865-1868.
18. Chen M-L, Lesko LK. (2001) Individual bioequivalence revisited. Clin Pharmacokinet 40:701-706.
19. Chen M-L, Yu L. (2009) The use of drug metabolism for predicting intestinal permeability. Mol Pharm 6:74-81.
20. Chuang K, Krauss GL, Cao YJ. (2009) Evaluating FDA bioequivalence standards for generic carbamazepine formulations. Neurology, 72:A226.
21. Crawford P, Feely M, Guberman A, Kramer G. (2006) Are there potential problems with generic substitution of antiepileptic drug:? a review of issues Seizure 15:165-176.
22. Davit BM. (2007) Current thinking of the US-FDA on bioequivalence of highly variable drugs. EUFPES & COST B24 conference; bioavailability (BA) and bioequivalence (BE)Focus on physiological factors and variability, 2007, Athens, October 1-2, 2007
23. Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkind MB, Wan GP, Rupnow MFT, LeLorier J. (2009) The risks and cost of multiple-generic substitution of topiramate. Neurology, 72:2212-2219.
24. Endrenyi L, Midha KK. (1998) Individual bioequivalence- has it time come? European J. Pharm Sci 6:271-277.
25. Endrenyi L, Amidon GL, Midha KK, Skelly JP. (1998) Individual bioequivalence; Attractive in principle, difficult in practice. Pharm Res 15:1321-1325.
26. FDA. (2002) Process for Approving Generic Drugs. October 29, 2002. Available at: http:/http://www.fda.gov/cder/ogd-10-BCBS-gjb, Accessed January 28 2009.
27. Food and Drug Administration. (2000) Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release solid dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD, 2000. Available at: http://www.fad.gov/cder/ guidance/index/htm.
28. Haider SH, Davit B, Chen M-L, Conner D, Lee LM, Li QH, Lionberger R, Makhlouf F, Patel D, Schurimann DJ, Yu LX. (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25:237-241.
29. Hauck WW, Anderson S. (1997) Commentary on individual bioequivalence by M-L Chen. J Biopharm Stat 7:13-16.
30. Henney JE. (1999) Review of generic bioequivalence studies. JAMA 282:1995-1995.
31. Jobst BC, Holmes GL. (2004) Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18:617-628.
32. Johannessen SI, Batino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN. (2003) Therapeutics drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347-363. (Pubitemid 36638181)
33. Kramer G, Schneble H, Wolf P; Ad-hoc-Kommission der Deutschen Sekton der Internationalen Liga Gegen Epilepsie. (2002) Risken der neuen Aut-idem-Regelung fur die Behandlung mit Antiepileptika. Akt Neuerol 29:115-122.
34. Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW. (2007) Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss Branches of the ILAE. Epilepsia; 48:609-611.
35. Lesser RP, Krauss G. (2001) Buy some today: can generic be safely substituted for brand-name drugs? Neurology 57:571-573.
36. Ligue Francaise Contre L'Epilepsie (LFCE). (2007) Recommendation on the use of generic for the treatment of epilepsy. http://www.lfce-epilepsies. fr, or http://www.ilae-epilepsy.org, October, 2007.
37. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. (2007) Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68:1249-1250. (Pubitemid 46625968)
38. Midha KK, Rawson MJ, Hubbard JW. (1997) Individual and average bioequivalence of highly variable drugs and drug products. J Pharm Sci 86:1193-1197.
39. Midha KK, Rwason MJ, Hubbard JW. (2005) The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmamcol Ther, 43:485-498.
40. Midha KK, Rawson MJ, Hubbard JW. (2006) Bioequivalence measures and parameters, criteria for comparisons, ABE and IBE. In: Amidon G, Lesko L, Midha KK, Shah V, Hilfinger J, (Eds) International bioequivalence standards: a new era., TSRL Inc., Ann Arbor; pp. 147-160.
41. Midha KK, Shah VP, Singh GJP, Patnaik R. (2007) Conference Report: Bio-International 2005. J Pharm Sci 96:747-754.
42. Nightingale SL, Morrsion JC. (1987) Generic drugs and prescribing physician. JAMA 258:1200-1204.
43. Nightingale SL. (2001). Therapeutic equivalence of generic drugs: letter to health practitioners. Available at: hhttp://www.fda.gov/cder/news/ nightentlett.htm. (Accessed May 1, 2009).
44. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. (2008) Antiepileptic drugs - best practice guidance for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239-1276.
45. Perucca E, Albani F, Capovilla G, Dalla Bernardina B, Michelucci R, Zaccara G. (2006) Recommendation of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. Epilepsia 47(Suppl. 5):16-20.
46. Privitera MD. (2008) Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr. 8:113-117.
47. Privitera MD. (2009) Generics: is there a way to compare them to brand drugs? Antiepileptic drug trials X syllabus coral gables, April 15-17, 2009.
48. Rubinstein S. (2007) Industry fights switch to generics for epilepsy. Wall Street J 13:A1-A10.
49. Schuirmann DJ. (1987) A comparison of the two-one-sided tests procedure and the power approach for assessing equivalence of average bioavailability. J Pharmacokinet Biopharm 18:657-680.
50. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon G. (2006) A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain and Japan. Mol Pharm 3:631-643. (Pubitemid 46087480)
51. Williams RL. (1997) Therapeutic equivalence of generic drugs response to national association of boards of pharmacy. FDA, CEDAR, April 16, 1997.
52. Williams RL, Chen M-L, Hauck WW. (2002) Equivalence approaches. Clin Pharmacol Ther 72:229-237.
53. Wilner AN. (2002) Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 3:522-525.
54. Wilner AN. (2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5:995-998.
55. Wolf P. (2007). Political campaign in Denmark. In: Abstract book from the 27th international epilepsy congress in Singapore, July 8th-12th, 2007 July: 8-9.
56. Wolf P. (2008) Should newly diagnosed epilepsy be treated with generics? Nature Clin Pract 4:176-177.
57. Wu C-Y, Benet LZ. (2005) Predicting drug disposition via application of BCS: transport/absorption elimination interplay and development of biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
58. Zachry WM III, Quynhchau DD, Clewell JD, Smith BJ. (2009) Case-control analysis of ambulance, emergency room, or in inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50:493-500.